GlassScriptPhysician profile
Katherine A Thiel
NPI 1134702780
$2,341.22
in general payments reported to CMS, 2019-2025
42 companies · $1,778 in 2025
The $1,778 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $563 · 2025: $1,778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,291 · Education: $49.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,291.23 |
| Education | $49.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $238.07 | 2024-2025 | Imfinzi, Calquence, Lynparza |
| Novartis Pharmaceuticals Corporation | $171.91 | 2024-2025 | |
| Celgene Corporation | $160.65 | 2025 | Reblozyl, Breyanzi |
| Merck Sharp & Dohme LLC | $143.87 | 2024-2025 | Keytruda, Lynparza, Prevymis |
| Incyte Corporation | $128.18 | 2024-2025 | Monjuvi, Jakafi |
| Janssen Biotech, INC. | $126.00 | 2024-2025 | Tecvayli, Talvey, Darzalex |
| Takeda Pharmaceuticals U.S.A., INC. | $104.37 | 2025 | Iclusig, Fruzaqla, Hyqvia |
| Sobi, INC | $73.36 | 2024-2025 | |
| Taiho Oncology, INC. | $72.39 | 2024-2025 | |
| Novo Nordisk INC | $66.43 | 2024-2025 | Esperoct |
| Stemline Therapeutics INC. | $65.85 | 2024-2025 | Orserdu |
| Alnylam Pharmaceuticals INC. | $64.26 | 2024-2025 | Givlaari |
| Alexion Pharmaceuticals, INC. | $63.63 | 2024-2025 | Ultomiris |
| Genentech USA, INC. | $61.70 | 2025 | Venclexta, Polivy |
| Astellas Pharma US INC | $59.77 | 2025 | Vyloy |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $52.98 | 2025 | Xpovio |
| Daiichi Sankyo INC. | $49.98 | 2025 | Enhertu |
| Aveo Pharmaceuticals, INC. | $43.19 | 2025 | |
| Agios Pharmaceuticals, INC. | $43.04 | 2024-2025 | Pyrukynd |
| Jazz Pharmaceuticals INC. | $39.35 | 2024-2025 | |
| Pfizer INC. | $39.18 | 2024-2025 | |
| Glaxosmithkline, LLC. | $38.77 | 2025 | Zejula, Jemperli, Ojjaara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.91 | 2025 | |
| Abbvie INC. | $30.65 | 2025 | |
| Geron Corporation | $27.01 | 2025 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $26.04 | 2025 | Libtayo |
| Pharmaessentia USA Corporation | $25.16 | 2024 | Besremi |
| Rigel Pharmaceuticals, INC. | $22.17 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Tempus Ai, INC | $21.47 | 2024 | |
| Sanofi-Aventis U.S. LLC | $21.40 | 2025 | |
| Lilly USA, LLC | $21.28 | 2025 | Jaypirca, Verzenio |
| Exelixis INC. | $20.86 | 2025 | Cabometyx |
| Recordati_rare_diseases_inc. | $20.53 | 2024 | Sylvant |
| Blueprint Medicines Corporation | $19.80 | 2024 | Ayvakit |
| Invivyd INC | $19.42 | 2025 | Pemgarda |
| Kedrion Biopharma, INC. | $19.18 | 2024 | Gammaked, Kedrab, Koate |
| Emmaus Medical, INC. | $18.46 | 2025 | Endari |
| Kite Pharma, INC. | $18.19 | 2025 | Yescarta |
| Array Biopharma INC | $17.13 | 2024 | Braftovi, Tukysa, Mektovi |
| Genzyme Corporation | $16.38 | 2025 | |
| Servier Pharmaceuticals LLC | $16.27 | 2025 | |
| Genmab U.S., INC. | $15.98 | 2024 | Epkinly |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Thiel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.